Anti-P-selectin antibodies
AssigneesSelexys Pharmaceuticals Corporation, Oklahoma Medical Research Foundation
InventorsScott Rollins, Richard Alvarez, Russell Rother, Rodger P. McEver, Ziad S. Kawar
Life of this patent
Estimating the term…
Loading patent…
AssigneesSelexys Pharmaceuticals Corporation, Oklahoma Medical Research Foundation
InventorsScott Rollins, Richard Alvarez, Russell Rother, Rodger P. McEver, Ziad S. Kawar
Estimating the term…
Antibodies are disclosed which bind specifically to P-selectin and which block the binding of PSGL-1 to P-selectin. These anti-P-selectin antibodies may also cause dissociation of preformed P-selectin/PSGL-1 complexes. The disclosure identifies a heretofore unrecognized, near N-terminal, antibody binding domain (a conformational epitope) of P-selectin to which the function-blocking antibodies (which may be chimeric, human or humanized antibodies for example) bind. Antibodies are disclosed which bind to the conformational epitope of P-selectin and which have a dual function in blocking binding of PSGL-1 to P-selectin, and in causing dissociation of preformed P-selectin/PSGL-1 complexes. Such single and dual function anti-P-selectin antibodies and binding fragments thereof may be used in the treatment of a variety of inflammatory and thrombotic disorders and conditions. Screening methods for identifying such antibodies are also disclosed.
An isolated antibody or binding fragment thereof which specifically binds to a conformational epitope of P-selectin, wherein the conformational epitope is within amino acid positions 1-35 of SEQ ID NO:1,
Dependencies are inferred from the claim text.